Biologics for rare inflammatory diseases: TNF blockade in the SAPHO syndrome

Netherlands Journal of Medicine

Volumn 70, Issue 10, 2012, Pages 444-449

  Burgemeister, L T ^a   Baeten, D L P ^a   Tas, S W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acne; Anti TNF; Hidradenitis suppurativa; Hyperostosis; Osteitis; Pustulosis; SAPHO; Synovitis

Indexed keywords

ALENDRONIC ACID; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TECHNETIUM; TUMOR NECROSIS FACTOR INHIBITOR;

ACNE; ADULT; ARTHRITIS; CASE REPORT; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; GENETIC SCREENING; HIDRADENITIS; HUMAN; HUMAN TISSUE; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PUSTULOSIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; SAPHO SYNDROME; SCINTIGRAPHY; SKIN BIOPSY; SKIN DEFECT; SKIN SCAR; SYNOVITIS; THORAX PAIN;

ACQUIRED HYPEROSTOSIS SYNDROME; ADULT; BIOLOGICAL PRODUCTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871453004     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic. 1987;54:187-96.
2. Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford). 2004;43:1246-51.
3. Colina M, La CR, Trotta F. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol. 2009;27:112-5.
4. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 2009;61:813-21.
5. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29:159-71.
6. Salles M, Olive A, Perez-Andres R, et al. The SAPHO syndrome: a clinical and imaging study. Clin Rheumatol. 2011;30:245-9.
7. Magrey M, Khan MA. New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Curr Rheumatol Rep. 2009;11:329-33.
8. Rozin AP, Hasin T, Toledano K, Guralnik L, Balbir-Gurman A. Seronegative polyarthritis as severe systemic disease. Neth J Med. 2010;68:236-41.
9. Gonzalez T, Gantes M, Bustabad S, Diaz-Flores L. Acne fulminans associated with arthritis in monozygotic twins. J Rheumatol. 1985;12:389-91.
10. Dumolard A, Gaudin P, Juvin R, Bost M, Peoc'h M, Phelip X. SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford). 1999;38:463-7.
11. Eyrich GK, Langenegger T, Bruder E, Sailer HF, Michel BA. Diffuse chronic sclerosing osteomyelitis and the synovitis, acne, pustolosis, hyperostosis, osteitis (SAPHO) syndrome in two sisters. Int J Oral Maxillofac Surg. 2000;29:49-53.
12. Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet. 2005;42:551-7.
13. Hayem G. Valuable lessons from SAPHO syndrome. Joint Bone Spine. 2007;74:123-6.
14. Rozin AP. SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended? Arthritis Res Ther. 2009;11:131.
15. Kotilainen P, Merilahti-Palo R, Lehtonen OP, et al. Propionibacterium acnes isolated from sternal osteitis in a patient with SAPHO syndrome. J Rheumatol. 1996;23:1302-4.
16. Assmann G, Kueck O, Kirchhoff T, et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther. 2009;11:R140.
17. Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P, et al. Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients. J Rheumatol. 2010;37:639-43.
18. Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin Investig Drugs. 2006;15:1229-33.
19. Solau-Gervais E, Soubrier M, Gerot I, et al. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford). 2006;45:339-42.
20. Ben AK, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol. 2010;37:1699-704.
21. Hayem G, Ben M'Barak R, Toussirot E, Compaore C, Pham T. SAPHO syndrome treated by TNF alpha-blocking agents: report of 45 cases. Arthritis Rheum. 2010;62:S2269.
22. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis. 2010;69:2067-73.
23. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426-37.
24. Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis. 2012;71:1098-100.